Sortase recognition sequences enable covalent targeting molecule conjugation to AAV capsids while maintaining production yield.
Trans-pseudotyping produces recombinant AAV particles by infecting host cells with first-stage viral vectors to deliver genomes for second-stage encapsidation.
Viral transduction of somatic cells generates autologous pluripotent stem cells, eliminating immune rejection risks associated with embryonic sources.
Hybrid vectors merge arabinose regulation with translational enhancement elements, resolving the trade-off between tight control and high productivity.
AAV vectors delivering AUF1 stabilize the sarcolemma and promote slow-twitch fiber formation to reverse atrophy.
Self-assembling capsid proteins form nanocapsules that ferry orexin mRNA across the blood-brain barrier to treat neurodegenerative diseases.
Engineered transgene cassettes integrate efficiently into the host genome via retroviral integrase, bypassing viral immunogenicity and size constraints.
A replication-defective HSV-2 vaccine uses dominant-negative mutants to elicit broad immune responses.
A nucleic acid construct links a cardiac stress promoter to a mitochondrial targeting sequence for precise gene delivery.
A SspH1-based protein degradation system utilizing NEL and HR1b domains to target specific proteins in plant cells.
AAVhu68 capsids protect hGLA sequences and enable targeted uptake, solving stability and variable delivery issues in Fabry disease treatment.
Synthetic regulatory nucleic acid molecules confer reduced constitutive expression, eliminating inducer dependency and resolving plasmid yield limitations.
Engineered mesenchymal cells express the decoy receptor Decorin to bind TGF-β and inhibit fibrotic tissue progression.
Novel sorghum cytochrome P450 enzymes convert pentadecatrienyl resorcinol to dihydrosorgoleone.
A transgenic RGMc knockout mouse model enables detection of iron accumulation mechanisms through targeted gene disruption in embryonic stem cells.
A recombinant genetic construct uses microRNA target sites to regulate therapeutic gene expression in cancer cells.
Deoptimized AAV Rep78 sequences resolve adenoviral inhibition, enabling stable hybrid virus production.
An AAV1 vector delivers caspase-1 to induce pyroptosis in schwannoma cells.
Genetically modified pluripotent stem cells evade immune rejection through targeted gene knockout and CD47 overexpression.
An expression vector uses an internal ribosome entry site to drive glutamine synthetase for cell selection.
A nucleic acid sequence drives gene expression in rod photoreceptors using a specific promoter.
KoRV envelope glycoproteins pseudotype lentiviral vectors to transduce natural killer cells without pre-activation.
Segmented hypercascade arrays enable deep lineage reconstruction over long time scales while maintaining spatial context.
Engineered untranslated regions control AAV capsid and replication protein expression ratios.
Circular RNA constructs express urate oxidase via intron-mediated splicing, reducing immunogenicity compared to foreign protein sources.
A hybrid promoter merges a murine CMV enhancer with a rat EF-1alpha intron to drive recombinant protein expression in mammalian host cells.
Hepatitis B virus-derived cis-regulatory elements boost protein expression levels across diverse cell types without altering transcriptional rates.
Self-limiting rAAV vectors incorporate endonuclease recognition sequences, limiting vector persistence and preventing immune responses.
The hHLA promoter resolves insufficient transgene expression in immune cells by incorporating NF-kappaB and AP-1 binding sites.